Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSImmunology is the second largest therapy area by value and forecast to reach $156 billion globally by the end of 2023, at ex-manufacturer prices. Over the past 5 years, immunology enjoyed stellar growth at 15% CAGR, or over 3 times the rate of the overall pharmaceutical market. It has given rise to numerous blockbuster brands which harnessed the potential of multi-indicationality (a ‘pipeline in a product’), most notably AbbVie’s Humira, which generated over $20 billion in annual, global revenue at list price.
However, overall immunology growth is expected to slow down dramatically over the next 5 years to 4-6% CAGR (2022-2027), as the underlying business fundamentals are disrupted while innovators will have to navigate a much harsher competitive environment (see Figure 1).
Within immunology, it is important to note the starkly different growth prospects of the underlying autoimmune vs. inflammation market. Future growth of the larger ($132 billion in 2022), more mature autoimmune market is forecast at ~4% CAGR (2022-2027), while the smaller ($18 billion in 2022), less developed inflammation market is expected to grow at 3-4 times that rate, i.e., 12-15% CAGR, over the same time period.
Autoimmune: From hyper-growth to growth pocketsLong-dominating, first-generation innovation in the autoimmune market is maturing, as major flagship brands are facing LoE. Especially the entry of biosimilars of leading brands Humira, in the U.S., and Stelara will introduce low(er) cost options for two backbone mechanisms of action, anti-TNF and IL-12/23, across major autoimmune indications, including RA, IBD, PsO, PsA. Those biosimilars will exert downward price pressure beyond the originators to erode top-line market growth and will have profound implications for sequencing of therapy options, as payers seek to push biosimilars for first-line use, thus relegating newer, innovative therapies to later lines.
At the same time, all major autoimmune indications face extensive crowding as the next wave of innovation is jostling for position, with intensifying inter- and intra-class competition as therapy options proliferate. For example,
Such abundance of choice gives payers more leverage to extract value, as illustrated, for example, in the widening gross-to-net gap in the U.S. In 2022, average off-invoice concession by manufacturers exceeded 50% in immunology for the first time ever.
Innovators will need to carefully carve out their place in increasingly complex treatment algorithms, with high-stakes head-to-head data becoming critical to demonstrate superiority vs. leading competitors and/or the SoC to convince payers and HCPs, combined with RWE to pin-point patient segments of high unmet need who benefit the most from a given therapy.
Furthermore, the autoimmune market continues to be fiercely competitive, with total promotional investment exceeding $3 billion p.a. globally in each of the past 5 years, while in the U.S. market leading autoimmune brands consistently feature among the top 10 spenders on TV advertising and other direct to consumer (DTC) activities. Consequently, playing in the autoimmune market and rising above that noise level comes at a heavy cost to innovators.
Autoimmune innovators therefore face an unforgiving environment – squeezed between new low-cost options and a crowded innovation frontier. Such opportunity fragmentation also spells the likely end of the possibility of any future $10 billion+ autoimmune mega-blockbuster.
As white space in major autoimmune indications is disappearing, it is not surprising that innovators are increasingly looking elsewhere for new opportunities:
Two key trends are shaping the emerging innovation landscape and future competitive dynamics in immunology:
While more information is needed to understand the wider applicability of such biomarker-based approach, especially its feasibility in routine clinical practice, above examples may signal the arrival of precision medicine in immunology.
These innovation trends are also reflected in recent high-profile immunology deals:
The immunology market of the past is a foreign country, as new business realities take hold. Innovators must therefore move with the times to find success in a dramatically altered, much harsher and unforgiving environment.
Specifically, winning in crowded immunology indications requires:
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
